JNJ vs NVDA: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and NVIDIA Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
NVIDIA Corporation · Technology
$210.69
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
JNJ trades at a lower forward P/E
(29.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
NVDA |
| Current Price |
$253.85 |
$210.69 |
| Fair Value Estimate |
$198.76 |
$305.50 |
| Upside to Fair Value |
-21.7%
|
+45.0%
|
| Market Cap |
$611.1B |
$5,103.1B |
| Forward P/E |
29.3x
|
32.1x
|
| EV / EBITDA |
19.2x
|
26.5x
|
| Price / Sales |
6.3x
|
20.1x
|
| Price / FCF |
34.3x
|
42.9x
|
| Revenue Growth YoY |
+9.9%
|
+85.2%
|
| Gross Margin |
69.1%
|
74.1%
|
| Operating Margin |
26.9%
|
64.0%
|
| Return on Equity |
26.3%
|
111.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
2.33%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
NVIDIA Corporation is a leading technology company specializing in semiconductors, particularly GPUs and AI accelerators, with a dominant market position in AI training markets holding over 80% share. The company exhibits exceptional business quality with a founder-led management team boasting over 30 years of continuous leadership, very high profitability with gross margins above 74% and net mar…
Accumulation Zones
| Metric |
JNJ |
NVDA |
| Zone Low |
$149.07 |
$229.12 |
| Zone High |
$168.95 |
$259.68 |
| In Buy Zone? |
No
|
Yes
|